Evommune scraps eczema drug after trial miss, shares plunge

Evommune said on Tuesday it will not advance its experimental skin disease drug ​after it failed to meet the main ‌goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。